Alivus Life Sciences Limited (formerly Glenmark Life Sciences Limited) announced its audited financial results for the quarter and year ended March 31, 2026, during a board meeting held on May 14, 2026. The company reported a steady performance with revenue from operations reaching ₹6,891.17 million for the fourth quarter, compared to ₹6,495.45 million in the same quarter last year, marking a 6.09% YoY increase. Sequentially, revenue grew by 2.41% from ₹6,728.89 million in the December 2025 quarter. Profit after tax for Q4 FY26 stood at ₹1,552.37 million, reflecting a 12.19% YoY growth from ₹1,383.69 million and a 3.31% QoQ increase from ₹1,502.57 million. The board also recommended a final dividend of ₹5 per equity share (250%) for the 2025-26 fiscal year.

Alivus Life Sciences Limited is a prominent developer and manufacturer of high-value, non-commoditized Active Pharmaceutical Ingredients (APIs) in chronic therapeutic areas, including cardiovascular disease, central nervous system disorders, and pain management. On January 20, 2025, the company officially transitioned its name from Glenmark Life Sciences to Alivus Life Sciences following its acquisition by Nirma Limited, which now holds a majority stake. Throughout 2025, the company maintained its position as a net debt-free entity while expanding its presence in key global markets such as Europe and Japan. Recent strategic updates in 2025 highlighted new client wins in the contract development and manufacturing (CDMO) segment and a continued focus on its rich API portfolio as primary growth drivers. In early 2025, the company also reported the passing of its independent director, Mr. Vijaykumar Ratilal Shah.